B
Bernd W. Scheithauer
Researcher at Johns Hopkins University
Publications - 9
Citations - 4211
Bernd W. Scheithauer is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Oligodendroglioma & Progressive disease. The author has an hindex of 9, co-authored 9 publications receiving 4072 citations. Previous affiliations of Bernd W. Scheithauer include Washington University in St. Louis & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
The WHO Classification of Tumors of the Nervous System
Paul Kleihues,David N. Louis,Bernd W. Scheithauer,Lucy B. Rorke,Guido Reifenberger,Peter C. Burger,Webster K. Cavenee +6 more
TL;DR: The new World Health Organization (WHO) classification of nervous system tumors, published in 2000, emerged from a 1999 international consensus conference of neuropathologists, and new entities include chordoid glioma of the third ventricle, cerebellar liponeurocytoma, atypical teratoid/rhabdoid tumor, and perineurioma.
Journal ArticleDOI
Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas
Justin S. Smith,Arie Perry,Thomas J. Borell,Hyun K. Lee,Judith R. O'Fallon,Sandra M. Hosek,David W. Kimmel,Allan J. Yates,Peter C. Burger,Bernd W. Scheithauer,Robert B. Jenkins +10 more
TL;DR: Combined loss of 1p and 19q is a statistically significant predictor of prolonged survival in patients with pure oligodendroglioma, independent of tumor grade, and could potentially improve existing strategies for patient stratification and management.
Journal ArticleDOI
Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study
Evanthia Galanis,Jan C. Buckner,Matthew J. Maurer,Jeffrey I. Kreisberg,Karla V. Ballman,J. Boni,J. M. Peralba,Robert B. Jenkins,Shaker R. Dakhil,Roscoe F. Morton,Kurt A. Jaeckle,Bernd W. Scheithauer,Janet Dancey,Manuel Hidalgo,Daniel J. Walsh +14 more
TL;DR: Temsirolimus is well tolerated in recurrent GBM patients and high levels of phosphorylated p70s6 kinase in baseline tumor samples appear to predict a patient population more likely to derive benefit from treatment, and should be validated in other studies of mTOR inhibitors.
Journal ArticleDOI
Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177
Paul D. Brown,Sunil Krishnan,J. N. Sarkaria,Wenting Wu,Kurt A. Jaeckle,Joon H. Uhm,Francois J. Geoffroy,Robert M. Arusell,Gaspar J. Kitange,Robert B. Jenkins,John W. Kugler,Roscoe F. Morton,Kendrith M. Rowland,Paul S. Mischel,William H. Yong,Bernd W. Scheithauer,David Schiff,Caterina Giannini,Jan C. Buckner +18 more
TL;DR: Although the primary end point was successfully met using nitrosourea-based chemotherapy era historic controls, there was no sign of benefit in overall survival when comparing N0177 with the RT/TMZ arm of the European Organisation for Research and Treatment of Cancer/National Cancer Institute of Canada trial 26981/22981.
Journal ArticleDOI
Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities.
Jan C. Buckner,Dean H. Gesme,Judith R. O'Fallon,Julie E. Hammack,Scott Stafford,Paul D. Brown,Roland B. Hawkins,Bernd W. Scheithauer,Bradley J. Erickson,Ralph Levitt,Edward G. Shaw,Robert B. Jenkins +11 more
TL;DR: PCV produces tumor regressions in a meaningful proportion of patients with LGO/LGOA and loss of 1p and 19q seems limited to patients with pure LGO and is inversely related to p53 alterations.